Investing.com - Financial Markets Worldwide

Smith+Nephew appoints David King as non-executive director

Published 13/06/2025, 07:02
Smith+Nephew appoints David King as non-executive director
SN
-0.21%
SNN
-1.55%

LONDON - Medical (TASE:BLWV) technology company Smith+Nephew (LSE:SN, NYSE:SNN) announced Friday that David King will join its Board as an independent Non-Executive Director effective July 1, 2025.

King will serve as a member of the Compliance & Culture and Remuneration Committees, according to a press release statement from the company.

King currently serves as CEO, executive director and chair of Fortis (NYSE:FTS) Life Sciences. His board experience includes recent positions at several U.S. healthcare companies including ZimVie (2022-2025), VaxCare (2021-2025), Privia Health, Health Channels, LGC and AmSurg Corporation.

Prior to his current roles, King was executive chair and CEO for Laboratory Corporation of America (NYSE:LH) (LabCorp) from 2007 to 2020. He previously worked as a partner at Hogan & Hartson LLP, now known as Hogan Lovells.

Smith+Nephew Chair Rupert Soames stated in the announcement: "We are delighted to welcome David to our Board. He has extensive experience in the healthcare and life sciences sectors helping to transform and grow businesses in the US and globally."

Smith+Nephew, founded in Hull, UK in 1856, operates in approximately 100 countries and reported annual sales of $5.8 billion in 2024. The company employs 17,000 people across its three global business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.